Mark H Ebell1, Brian McKay2, Ariella Dale2, Ryan Guilbault2, Yokabed Ermias2. 1. Department of Epidemiology and Biostatistics, College of Public Health, the University of Georgia, Athens, Georgia ebell@uga.edu. 2. Department of Epidemiology and Biostatistics, College of Public Health, the University of Georgia, Athens, Georgia.
Abstract
PURPOSE: To evaluate the accuracy of signs and symptoms for the diagnosis of acute rhinosinusitis (ARS). METHODS: We searched Medline to identify studies of outpatients with clinically suspected ARS and sufficient data reported to calculate the sensitivity and specificity. Of 1,649 studies initially identified, 17 met our inclusion criteria. Acute rhinosinusitis was diagnosed by any valid reference standard, whereas acute bacterial rhinosinusitis (ABRS) was diagnosed by purulence on antral puncture or positive bacterial culture. We used bivariate meta-analysis to calculate summary estimates of test accuracy. RESULTS: Among patients with clinically suspected ARS, the prevalence of imaging confirmed ARS is 51% and ABRS is 31%. Clinical findings that best rule in ARS are purulent secretions in the middle meatus (positive likelihood ratio [LR+] 3.2) and the overall clinical impression (LR+ 3.0). The findings that best rule out ARS are the overall clinical impression (negative likelihood ratio [LR-] 0.37), normal transillumination (LR- 0.55), the absence of preceding respiratory tract infection (LR- 0.48), any nasal discharge (LR- 0.49), and purulent nasal discharge (LR- 0.54). Based on limited data, the overall clinical impression (LR+ 3.8, LR- 0.34), cacosmia (fetid odor on the breath) (LR+ 4.3, LR- 0.86) and pain in the teeth (LR+ 2.0, LR- 0.77) are the best predictors of ABRS. While several clinical decision rules have been proposed, none have been prospectively validated. CONCLUSIONS: Among patients with clinically suspected ARS, only about one-third have ABRS. The overall clinical impression, cacosmia, and pain in the teeth are the best predictors of ABRS. Clinical decision rules, including those incorporating C-reactive protein, and use of urine dipsticks are promising, but require prospective validation.
PURPOSE: To evaluate the accuracy of signs and symptoms for the diagnosis of acute rhinosinusitis (ARS). METHODS: We searched Medline to identify studies of outpatients with clinically suspected ARS and sufficient data reported to calculate the sensitivity and specificity. Of 1,649 studies initially identified, 17 met our inclusion criteria. Acute rhinosinusitis was diagnosed by any valid reference standard, whereas acute bacterial rhinosinusitis (ABRS) was diagnosed by purulence on antral puncture or positive bacterial culture. We used bivariate meta-analysis to calculate summary estimates of test accuracy. RESULTS: Among patients with clinically suspected ARS, the prevalence of imaging confirmed ARS is 51% and ABRS is 31%. Clinical findings that best rule in ARS are purulent secretions in the middle meatus (positive likelihood ratio [LR+] 3.2) and the overall clinical impression (LR+ 3.0). The findings that best rule out ARS are the overall clinical impression (negative likelihood ratio [LR-] 0.37), normal transillumination (LR- 0.55), the absence of preceding respiratory tract infection (LR- 0.48), any nasal discharge (LR- 0.49), and purulent nasal discharge (LR- 0.54). Based on limited data, the overall clinical impression (LR+ 3.8, LR- 0.34), cacosmia (fetid odor on the breath) (LR+ 4.3, LR- 0.86) and pain in the teeth (LR+ 2.0, LR- 0.77) are the best predictors of ABRS. While several clinical decision rules have been proposed, none have been prospectively validated. CONCLUSIONS: Among patients with clinically suspected ARS, only about one-third have ABRS. The overall clinical impression, cacosmia, and pain in the teeth are the best predictors of ABRS. Clinical decision rules, including those incorporating C-reactive protein, and use of urine dipsticks are promising, but require prospective validation.
Authors: Saskia F van Vugt; Berna Dl Broekhuizen; Nicolaas Pa Zuithoff; Gerrit A van Essen; Mark H Ebell; Samuel Coenen; Margareta Ieven; Christine Lammens; Herman Goossens; Chris C Butler; Kerenza Hood; Paul Little; Theo Jm Verheij Journal: Fam Pract Date: 2015-06-04 Impact factor: 2.267
Authors: Carl Llor; Lars Bjerrum; Javier Arranz; Guillermo García; Josep Maria Cots; Beatriz González López-Valcárcel; María José Monedero; Manuel Gómez; Jesús Ortega; Gloria Guerra; Marina Cid; José Paredes; Vicenta Pineda; Carolina Pérez; Juan de Dios Alcántara; Silvia Hernández Journal: Fam Pract Date: 2012-03-23 Impact factor: 2.267
Authors: Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Francisco Fernández-Campos; Beatriz Clares; María J Rodríguez-Lagunas; Olga Jauregui; Isidre Casals; Ana C Calpena Journal: Pharmaceutics Date: 2019-08-21 Impact factor: 6.321
Authors: Roderick Venekamp; Jens Georg Hansen; Johannes B Reitsma; Mark H Ebell; Morten Lindbaek Journal: BMJ Open Date: 2020-11-03 Impact factor: 2.692
Authors: Roderick P Venekamp; Jeroen Hoogland; Maarten van Smeden; Maroeska M Rovers; An I De Sutter; Daniel Merenstein; Gerrit A van Essen; Laurent Kaiser; Helena Liira; Paul Little; Heiner Cc Bucher; Johannes B Reitsma Journal: BMJ Open Date: 2021-07-01 Impact factor: 2.692